Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously ...
Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...
NPM-115 (exenatide implant) generated significant weight loss comparable to injectable semaglutide (Ozempic®/Wegovy®) from a single administration with expected twice-yearly dosing Vivani discloses ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest trial ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers. The world’s largest and longest trial ...
Study over 24 weeks on patients with type 2 diabetes Says exenatide once-weekly shows superior glucose control Dec 15 (Reuters) - Amylin Pharmaceuticals Inc reported positive data from a study that ...
The co and Eli Lilly (LLY) announces the FDA has approved more convenient patient storage instructions for BYETTA (exenatide) injection. BYETTA Pens can now be kept at a room temperature not to exceed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback